EGFR exon 19 deletion is associated with favorable overall survival after first-line icotinib therapy in advanced NSCLC patients

Category Primary study
JournalJournal of Thoracic Oncology
Year 2017
This article has no abstract
Epistemonikos ID: bf7cd72985a328d053ca32ce12e57331b01e888f
First added on: Feb 08, 2025